# Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

> **NCT01153672** · NA · COMPLETED · sponsor: **University of Washington** · enrollment: 8 (actual)

## Conditions studied

- Male Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** vorinostat
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** biopsy
- **RADIATION:** F-18 16 alpha-fluoroestradiol
- **PROCEDURE:** positron emission tomography
- **DRUG:** anastrozole
- **DRUG:** letrozole
- **DRUG:** exemestane
- **GENETIC:** gene expression analysis

## Key facts

- **NCT ID:** NCT01153672
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-07
- **Final completion:** 2016-08-11
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01153672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01153672, "Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01153672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*